Western blotting analysis showed complete knockout of FGL2 expression in glioma (GL261-FGL2KO) and Lewis lung cancer cells (LLC-FGL2KO) and downregulated FGL2 expression in FGL2-knockdown astrocytoma cells (DBT-FGL2KD) compared with the cognate cells in which the non-targeting control sequence was introduced via the same technology (Fig. 2b). The gene discussed is FGL2; the disease is astrocytoma (excluding glioblastoma).